Nivolumab for the Treatment of Patients with Metastatic Non‐Clear Cell Renal Cell Carcinoma (nccRCC): A Single‐Institutional Experience and Literature Meta‐Analysis

INTRODUCTION: Nivolumab alone and in combination with ipilimumab is approved for the treatment of patients with metastatic renal cell carcinoma (RCC) who received prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR‐TKI) and those who are treatment naive, respectively....

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncologist
Κύριοι συγγραφείς: Chahoud, Jad, Msaouel, Pavlos, Campbell, Matthew T., Bathala, Tharakeswara, Xiao, Lianchun, Gao, Jianjun, Zurita, Amado J., Shah, Amishi Yogesh, Jonasch, Eric, Sharma, Padmanee, Tannir, Nizar M.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: John Wiley & Sons, Inc. 2019
Θέματα:
Genitourinary Cancer
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066696/
https://ncbi.nlm.nih.gov/pubmed/32162795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0372
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια